
MASI
USDMasimo Corporation Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$162.240
最高
$163.890
最低
$161.480
交易量
0.00M
公司基本面
市值
8.8B
行業
醫療器材
國家
United States
交易統計
平均交易量
0.59M
交易所
NMS
貨幣
USD
52週範圍
AI分析報告
最後更新: 2025年4月27日MASI (Masimo Corporation Common Stock): Analyzing Recent Moves & What Might Come Next
Stock Symbol: MASI Generate Date: 2025-04-27 02:22:53
Alright, let's break down what's been going on with Masimo stock based on the latest info we've got. We'll look at the news, the price chart, and what some AI is predicting.
Recent News Buzz: Not Much Shaking Here
The news flow for Masimo lately seems pretty quiet, at least based on what's provided. We saw Needham, an analyst firm, basically stick to their "Hold" rating back on April 10th. Think of a "Hold" rating as saying, "Yeah, things are okay, nothing major screaming buy or sell right now." It's a neutral stance, not really pushing the stock one way or the other.
There was also news about Dexcom, a different company in the healthcare space, appointing a new chief commercial officer. While it's good to know what competitors are up to, this specific piece of news about Dexcom's internal hiring doesn't really tell us much directly about Masimo's business or stock prospects.
So, the takeaway from the news? It's mostly a non-event. No big positive or negative catalysts popping up from these headlines.
Price Check: A Wild Ride, Then a Recent Climb
Looking at the stock's journey over the past few months, it's been quite volatile. After climbing nicely through January and February, hitting a peak around the $190 mark in late February, things took a turn. The price dropped significantly in March and then saw a really sharp plunge in early April, dipping down into the low $140s and even high $130s around April 7th.
Since that early April low point, the stock has been working its way back up. The last few trading days in April show a clear upward push, moving from the low $150s towards the mid-$160s. The last recorded price was $163.74 as of April 25th.
So, the recent trend is definitely positive, showing some recovery and momentum after that earlier steep fall.
Now, what about the AI's crystal ball? The prediction model suggests the stock might stay flat today (0.00% change), then see a small dip tomorrow (-0.26%), followed by a slightly larger dip the day after (-1.73%). This contrasts a bit with the recent upward price action we just saw.
Putting It Together: What Does This Mean?
Okay, let's connect the dots. We have neutral news, a recent price chart showing good upward momentum after a big drop, and an AI prediction that calls for a slight pullback soon.
This creates a bit of a mixed picture. The recent price strength and the bullish technical signals mentioned in the recommendation data (like the MACD Golden Cross and strong volume on some days) suggest there's buying interest right now. However, the AI prediction hints that this recent bounce might face some near-term selling pressure. Also, it's worth noting the company's fundamentals, like revenue growth and return on equity, aren't looking super strong according to the recommendation data, and debt is relatively high.
Given the recent upward move but the AI's forecast for a dip, the situation isn't a screaming "buy everything now" or "sell everything immediately." It might lean towards a "watch and wait" approach, or perhaps looking for potential entry points if the predicted dip occurs.
- Potential Strategy Idea (Cautious): If you're thinking about getting in, and you trust the AI's short-term prediction, you might consider waiting to see if the stock pulls back a bit towards the lower end of the recent trading range or the recommended entry levels (around $162-$163). Waiting for a dip could offer a better price if the AI is right.
- Managing Risk: For anyone holding or considering a position, setting a stop-loss is always smart. The recommendation data suggests a potential stop-loss level around $153.58. This level is below the recent consolidation area before the latest surge, so a drop below it might signal the recent momentum is fading.
- Potential Upside Target: The recommendation data also points to a potential take-profit level around $167.03. This is close to recent highs and could be a point to consider if the upward trend continues briefly.
Remember, these are just potential ideas based on the data points we have. The market can do anything.
Company Context: What Masimo Does
Just a quick reminder about Masimo itself: They're a healthcare technology company, big in patient monitoring devices (like pulse oximeters) and hospital automation. Their business is tied to the healthcare sector. The company has a market cap of around $8.8 billion, and its PE ratio is around 35x, which the recommendation data calls "neutral." It's had a wide trading range over the past year, from about $101 to $194. Knowing they are in medical devices helps understand why things like hospital spending or new device approvals can impact them.
Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.
相關新聞
Needham Reiterates Hold on Masimoto Hold
Needham analyst Mike Matson reiterates Masimo from Hold to Hold.
Dexcom Appoints Jon Coleman as Chief Commercial Officer
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global
AI預測Beta
AI推薦
更新於: 2025年4月27日 下午09:23
64.0% 信心度
風險與交易
入場點
$162.29
獲利了結
$167.03
止損
$153.58
關鍵因素
相關股票
保持更新
設定價格提醒,獲取AI分析更新和即時市場新聞。